.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC07_Tocilizumab.Tocilizumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC07_Tocilizumab.Tocilizumab| name: | Tocilizumab |
| ATC code: | L04AC07 | route: | intravenous |
| n-compartments | 2 |
Tocilizumab is a recombinant humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist. It is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome, and it has been used during the COVID-19 pandemic for severe inflammatory responses. Tocilizumab is administered primarily via intravenous infusion or subcutaneous injection.
Pharmacokinetic parameters based on two-compartment model in patients with rheumatoid arthritis after a single intravenous dose. The data are pooled from clinical studies in adult human subjects.
Bastida, C, et al., & Soy, D (2018). Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. British journal of clinical pharmacology 84(4) 716–725. DOI:10.1111/bcp.13500 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29314183
Arrivé, C, et al., & Djerada, Z (2024). A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 38(5) 703–716. DOI:10.1007/s40259-024-00676-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/39147956
Moes, DJAR, et al., & van Paassen, J (2022). Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Clinical pharmacokinetics 61(2) 231–247. DOI:10.1007/s40262-021-01074-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34633645